Trial Profile

Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dihydroartemisinin/piperaquine (Primary) ; Chloroquine; Tafenoquine
Indications Falciparum malaria
Focus Therapeutic Use
Acronyms ACTQ

Most Recent Events

16 May 2025 Planned End Date changed from 31 Aug 2025 to 31 Aug 2026.
16 May 2025 Planned primary completion date changed from 28 Feb 2025 to 28 Feb 2026.
05 Mar 2024 Planned number of patients changed from 388 to 606.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com